Equest – Trademark Portfolio

Entity Type: 99

Equest holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 7 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include EQUEST. The owner is based in Wylie, TX.

3800 Troy Road

Wylie, TX 75098

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Equest's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

41
Education & Entertainment (7 filings)

Education; providing of training; entertainment; sporting and cultural activities

44
Medical Services (6 filings)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Equest have?

Equest has 13 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned, 9 cancelled.

What trademark classes does Equest file in?

Equest files trademarks across 3 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 44 (Medical Services), Class 42 (Computer & Scientific). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.

What are Equest's most well-known trademarks?

Equest's registered trademark portfolio includes well-known marks such as EQUEST. These are among 2 currently registered trademarks in the portfolio.

What is Equest's trademark registration success rate?

Equest has a 15% trademark registration rate, with 2 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.